MARKET

AKBA

AKBA

Akebia Therapeut
NASDAQ
0.9860
+0.0960
+10.79%
After Hours: 0.9850 -0.001 -0.10% 19:43 02/03 EST
OPEN
0.8500
PREV CLOSE
0.8900
HIGH
0.9940
LOW
0.8400
VOLUME
2.84M
TURNOVER
0
52 WEEK HIGH
2.930
52 WEEK LOW
0.2410
MARKET CAP
181.39M
P/E (TTM)
-1.1198
1D
5D
1M
3M
1Y
5Y
12 Health Care Stocks Moving In Thursday's Intraday Session
Benzinga · 3d ago
Akebia jumps 28% after FDA nod for GSK kidney disease therapy
Seeking Alpha · 3d ago
Travere Therapeutics: Upcoming 'PDUFA' Date For Kidney Disease Therapy Is Critical
Seeking Alpha · 01/26 17:05
BRIEF-Akebia Therapeutics, Its Unit, And Averoa Sas Entered Into License Agreement
Reuters · 12/28/2022 14:48
Akebia out-licenses ferric citrate product; terminates BioVectra supply deal
Seekingalpha · 12/28/2022 14:37
On Dec 22, Akebia Therapeutics Co's Unit & Biovectra Entered Into Termination & Settlement Agreement Terminating All Existing Agreements Between COS; Under The Terms Of Termination Agreement, Co Has Agreed To Pay To Biovectra A Total Of $32.5M
Benzinga · 12/28/2022 13:24
On Dec 22, Akebia Therapeutics Co's Unit, And Averoa SAS Entered Into A License Agreement; Pursuant To Deal, Granted Averoa Exclusive License To Develop, Commercialize Ferric Citrate In The European Economic Area, Turkey, Switzerland And U.S.
Benzinga · 12/28/2022 13:24
Akebia Therapeutics Signs Licensing Deal With Averoa
Akebia Therapeutics Signs Licensing Deal With Averoa
MT Newswires · 12/28/2022 12:13
More
About AKBA
Akebia Therapeutics, Inc. is a biopharmaceutical company. The Company is focused on producing medicines for people living with kidney disease. Its lead product candidate, vadadustat, is an oral therapy in development for the treatment of anemia due to chronic kidney disease (CKD). Vadadustat is an oral hypoxia-inducible factor prolyl hydroxylase inhibitor (HIF-PHI), designed to mimic the physiologic effect of altitude on oxygen availability. In addition, it has a commercial product, Auryxia (ferric citrate), which is marketed for two indications in the United States: the control of serum phosphorus levels in adult patients with dialysis-dependent (DD)-CKD or the hyperphosphatemia indication, and the treatment of iron deficiency anemia (IDA), in adult patients with non-dialysis dependent (NDD)-CKD or the IDA indication. Its ferric citrate is also approved and marketed in Japan as an oral treatment for the improvement of hyperphosphatemia in patients with CKD.

Webull offers kinds of Akebia Therapeutics Inc stock information, including NASDAQ:AKBA real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, AKBA stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading AKBA stock methods without spending real money on the virtual paper trading platform.